Organon & Co. (OGN)
Market Cap | 3.80B |
Revenue (ttm) | 6.40B |
Net Income (ttm) | 864.00M |
Shares Out | 257.95M |
EPS (ttm) | 3.33 |
PE Ratio | 4.42 |
Forward PE | 3.82 |
Dividend | $1.12 (7.61%) |
Ex-Dividend Date | Feb 24, 2025 |
Volume | 3,443,796 |
Open | 14.04 |
Previous Close | 14.13 |
Day's Range | 13.90 - 14.76 |
52-Week Range | 13.87 - 23.10 |
Beta | 0.72 |
Analysts | Hold |
Price Target | 20.80 (+41.3%) |
Earnings Date | May 1, 2025 |
About OGN
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]
Financial Performance
In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $20.8, which is an increase of 41.30% from the latest price.
News

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.

Why Organon Is A Top Pick For Income Investors
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three mont...

New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-...

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Organon: 7% Yield With A Bargain Basement Valuation
Organon is a compelling 'Buy' for value and income investors, trading at a deep discount with a forward P/E of 3.9x and a 7.3% dividend yield. OGN's diversified revenue streams in Women's Health, Bios...

Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Wa...

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024.

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025.

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth...

Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)
Organon & Co. (NYSE:OGN) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Confer...

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th.
Final Trades: Amazon, American Express and Organon
The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half.

Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has show...

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue g...

Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Wal...

Organon Reports Results for the Third Quarter Ended September 30, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings.

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%.

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Stocks to Buy for a Harris Presidency
The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, will release its third quarter 2024 financial results on October 31, 2024, prior to...
Final Trades: Organon, Howmet and the PSQ
The Investment Committee give you their top stocks to watch for the second half.

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.

Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.

Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.